Assessing urinary biomarkers in membranous glomerulonephritis
Correlation and Clinical Utility of Urinary Biomarker in Membranous Glomerulonephritis
This study is testing if urine samples can provide useful information about kidney health in people who have just been diagnosed with membranous glomerulonephritis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Shatin) |
| Trial ID | NCT05688865 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the correlation between urinary biomarkers and serum samples in patients with newly diagnosed membranous glomerulonephritis (MGN). Fifty patients will be recruited and followed for one year, during which serum and urinary biomarkers will be collected every four months and analyzed using ELISA assays. The primary outcome is to determine the correlation of urinary biomarkers with serum markers, while secondary outcomes include their relationship with clinical parameters such as eGFR decline and renal events. This research seeks to establish the clinical utility of urinary biomarkers as a non-invasive alternative to serum samples.
Who should consider this trial
Good fit: Ideal candidates are individuals with newly diagnosed biopsy-proven primary membranous glomerulonephritis.
Not a fit: Patients with secondary causes of membranous nephropathy, such as lupus nephritis or viral hepatitis, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method for detecting and monitoring membranous glomerulonephritis.
How similar studies have performed: While the use of serum biomarkers has been established, the clinical utility of urinary biomarkers in this context is still being explored, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * newly diagnosed biopsy proven primary membranous glomerulonephritis Exclusion Criteria: * secondary causes of membranous nephropathy, e.g. lupus nephritis, viral hepatitis B and C and malignancy
Where this trial is running
Shatin
- Department of Medicine & Therapeutics, Prince of Wales Hospital — Shatin, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Winston WS Fung, MBBS
- Email: fws898@ha.org.hk
- Phone: 35053528
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.